The Antibacterial Drug Market Analysis 2008-2013

Table of Contents

Chapter 1 Executive Summary

• 1.1 Market Review: Growth to 2013 Will Be Low
• 1.2 Cephalosporin' s Class Leads the Market
• 1.3 Aims, Scope and Format of the Report

Chapter 2 Introduction to Bacterial Infections

• 2.1 Bacteria: An Introduction
  • 2.1.1 Bacteria Classification
  • 2.1.2 What is Bacterial Infection?
  • 2.1.3 Bacterial Invasiveness
  • 2.1.4 Bacterial Toxigenicity
  • 2.1.5 Bacterial Virulence
  • 2.1.6 The Factors that Govern the Transmission of Bacterial Disease
  • 2.1.7 Clinically Important Bacteria
• 2.2 Bacterial Disease Statistics
  • 2.2.1 Infectious Diseases - Major Cause of Deaths Worldwide
  • 2.2.2 Risk Factors for Bacterial Infections
  • 2.2.3 Re-emergence of Infectious Diseases - A Major Global Threat
• 2.3 Definition of Antibacterials
• 2.4 The History of Antibacterials
  • 2.4.1 The Discovery of Penicillin
  • 2.4.2 Early Use of Penicillin
  • 2.4.3 Penicillin Resistance
  • 2.4.4 Discovery of Streptomycin, Chloramphenicol & Tetracycline
  • 2.4.5 Antibacterial Effects
• 2.5 The Leading Antibacterials
• 2.6 The Principal Mechanisms of Action of Antibacterials
  • 2.6.1 Antibacterials as Cell Wall Synthesis Inhibitors
  • 2.6.2 Antibacterials as Cell Membrane Inhibitors
  • 2.6.3 Antibacterials as Protein Synthesis Inhibitors
  • 2.6.4 The Effects of Antibacterials on Nucleic Acids
• 2.7 Antibiotics as Competitive Inhibitors
• 2.8 Antibacterial Classification by Chemical Structure
  • 2.8.1 Penicillin
  • 2.8.2 Semisynthetic Penicillins
  • 2.8.3 Carbapenems
  • 2.8.4 Cephalosporins
  • 2.8.5 Quinolones and Fluoroquinolones
  • 2.8.6 Tetracyclines
  • 2.8.7 Aminoglycosides
  • 2.8.8 Sulphonamides
  • 2.8.9 Macrolides
  • 2.8.10 Glycopeptides
  • 2.8.11 Oxazolidinones
• 2.9 Broad-Spectrum vs Narrow-Spectrum Antibiotics

Chapter 3 The World Market for Antibacterials 2008-2013

• 3.1 The Global Antibacterial Drug Market Will Decline During 2008-2013
• 3.2 Pfizer Currently Leads the Antibacterials Market
• 3.3 Cephalosporins to Continue Their Domination of the Antibacterials Market Despite Negative Growth
• 3.4 Miscellaneous Class Will Display High Revenues During 2006-2013
• 3.5 Levaquin is Currently the World' s Leading Antibacterial Agent - But will it Last?
• 3.6 Patent Expiry Will Reduce Growth Rates
• 3.7 Prescriptions for Antibiotics in the Developed World Are Falling
• 3.8 Pharmaceutical Companies Accept that Future Antibacterial Blockbuster Drugs Will Be Increasingly Rare
• 3.9 Generic Drugs Are Not Necessarily Cheap
• 3.10 Competition in the Antibacterials Drug Market to Become Increasingly Intense

Chapter 4 The World Market for Cephalosporins, 2008-2013

• 4.1 Cephalosporins Will Suffer From Patent Expiration
• 4.2 Abbott' s Omnicef Currently Leads the Cephalosporins Market
  • 4.2.1 Omnicef Will Lose Dominance in This Class to Maxipime
• 4.3 Rocephin Will Decline in Growth
  • 4.3.1 Rocephin Already Suffers From Generic Competition
• 4.4 Maxipime Sales Will be Affected by the Loss of Patent Protection

Chapter 5 The World Market for Fluoroquinolones, 2008-2013

• 5.1 Increased Competition Will Lower Revenues Among the Fluoroquinolones
• 5.2 Fluoroquinolones Linked With Side Effects
• 5.3 Will J&J' s Levaquin Still Dominate the Fluoroquinolones Market After Patent Expiration?
  • 5.3.1 Levaquin Faces Generic Competition
  • 5.3.2 Levaquin Approved for Urinary Tract Infections and Acute Pyelonephritis
• 5.4 Avelox Will Exhibit Steady Growth
  • 5.4.1 Head-to-Head Study Finds Avelox to be More Effective in Patients with CAP
  • 5.4.2 Avelox Monotherapy as Effective as Combination Therapy in Patients With Severe CAP
  • 5.4.3 Avelox Monotherapy as Effective as Multi-Dose Combination Therapy in Patients With cIAI
  • 5.4.4 Bayer Warns Doctors on Rare Avelox Side Effects
• 5.5 Ciproxin Will Decline in Growth
• 5.6 Cravit Will Gradually Decline in Sales

Chapter 6 The World Market for Broad Spectrum Penicillins, 2008-2013

• 6.1 Penicillins Will Retain Their Niche Despite a Marked Decline in Sales
• 6.2 Can GSK' s Augmentin Overcome Generic Competition?
  • 6.2.1 Why Will Augmentin' s Revenue Drop?
• 6.3 Tazocin Will Decline in Sales

Chapter 7 The World Market for Macrolides, 2008-2013

• 7.1 The Macrolides Will Face Decreased Growth
  • 7.1.1 Macrolides: Possible Extra-Infectious Indications May Expand the Market
  • 7.1.2 The Immunomodulatory Effects of Macrolides May Aid Revenue Growth
  • 7.1.3 Macrolides May Have a Clinical use in Other Chronic Lower Airway Diseases
• 7.2 Abbott' s Klacid/Biaxin Leads This Market
  • 7.2.1 Klacid/Biaxin Suffers From Generic Competition
• 7.3 Zithromax Faces Negative Growth
  • 7.3.1 Pfizer Petitions FDA to Recall Generic Azithromycin Products to Correct Misbranding
• 7.4 Can Azithromycin PFIZ Recover Revenues Lost From Zithromax?

Chapter 8 The World Market for Carbapenems. 2008-2012

• 8.1 Carbapenems Will See High Growth
• 8.2 Merck & Co' s Zienam Leads This Market
• 8.3 Merrem Exhibits Strong Growth
  • 8.3.1 Merrem Receives FDA Approval for Complicated Skin Infections

Chapter 9 The World Market for Miscellaneous Antibacterials, 2008-2013

• 9.1 Miscellaneous Antibacterials Will See High Growth as Sales Increases
• 9.2 Pfizer' s Zyvox Set to Reach Blockbuster Status
  • 9.2.1 Zyvox Will Overtake Levaquin to Become the New Market Leader in the Antibacterials Sector
• 9.3 Targocid Shows Some Positive Growth - But Will it Continue?
• 9.4 Vancocin Will Exhibit Negative Growth

Chapter 10 An Analysis of Factors That Influence the Antibacterials Market

• 10.1 SWOT Analysis of the Antibacterials Market
• 10.2 Drivers and Restraints on Market Growth
  • 10.2.1 Market Drivers
  • 10.2.2 Market Restraints
• 10.3 To What Extent is the Antibacterials Market Threatened by Generic Substitutes?
  • 10.3.1 The Threat of Generic Drugs to Brand Name Pharmaceuticals
• 10.4 Lifecycle Management Strategies Will Become More Prominent to Protect Soon-to-be off-Patent Drugs
• 10.5 Additional Indications for Currently Available Brands May be an Advantage
• 10.6 Antibacterial Resistance Is Due to Increased Infection Rates and Antibacterial Overuse
  • 10.6.1 Concerns Over Antibacterial Use
  • 10.6.2 FDA Measures on Bacterial Resistance
  • 10.6.3 Tackling Antibacterial Resistance
  • 10.6.4 The Use of Narrow Spectrum Antibacterials is the Best Strategy to Avoid Resistance
  • 10.6.5 Antibiotics in the US Carry Warnings Against Overuse
• 10.7 Comparative Studies - A Two Edged Sword
• 10.8 Challenges that Face Antibacterials Pharmaceutical Developers
• 10.9 Future Antibacterial Blockbuster Drugs is Increasingly Unlikely
• 10.10 Antibacterials in the Developing Countries
• 10.11 The Future of the Antibacterials Market - Closing Comments

Chapter 11 Antibacterials Pipeline Products

• 11.1 Summary of Antibacterials Pipeline Products From Phase II and Above
• 11.2 The Antibacterials Pipeline is Large
• 11.3 The Potential of the Antibacterials Market Has Encouraged R&D
• 11.4 Innovation Rules For Early Stage Pipeline Drugs
• 11.5 The FDA Will Fast Track New Antibacterials
• 11.6 Traditional Antibacterial Drugs are Less Popular
• 11.7 Promising Pipeline Drugs - Overview
  • 11.7.1 Middlebrook' s Moxatag
  • 11.7.2 Shogoo' s SPK 0602
  • 11.7.3 Pfizer' s Zeven (dalbavancin)
  • 11.7.4 Arpida' s Iclaprim
  • 11.7.5 Targanta' s Oritavancin
• 11.8 Gracevit Gets Approval for Manufacturing and Marketing
• 11.9 New Approaches to Antibacterial Drug Development
• 11.10 Antibacterial Pipeline Shows Short- and Long-Term Potential

Chapter 12 Conclusion

• 12.1 Patent Expiry of Brand Name Products Will Reduce Growth Rates
• 12.2 Cephalosporins to Continue Their Domination of the Antibacterials Market Despite Negative Growth
• 12.3 Future Antibacterial Blockbuster Drugs are Increasingly Unlikely
• 12.4 Market Drivers
• 12.5 Market Restraints
• 12.6 Opportunities in the Antibacterials Market
• 12.7 Antibacterials Pipeline Overview
• 12.8 The Future of the Antibacterials Market - Closing Comments

List of Tables

• Table 1.1 Top Ten Leading Antibacterials, by Revenues ($m), 2006
• Table 2.1 Clinically Important Bacteria
• Table 2.2 The Leading Antibacterials by Class, 2006
• Table 2.3 Antibiotic Action by Drug Class
• Table 3.1 World Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013, 2018 & 2023
• Table 3.2 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Antibacterial Drugs by Class, 2006 & 2013
• Table 3.3 The Leading Top Ten Antibacterials, 2006
• Table 4.1 World Revenues ($m) for Cephalosporin Drugs, 2008-2013, 2018 & 2023
• Table 4.2 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Cephalosporin Drugs, 2006 & 2013
• Table 5.1 World Revenues ($m) for Fluoroquinolones, 2008-2013, 2018 & 2023
• Table 5.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Fluoroquinolones, 2006 & 2013
• Table 6.1 World Revenues ($m) for Penicillins by Leading Products, 2008-2013, 2018 & 2023
• Table 6.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Penicillins, 2006 & 2013
• Table 7.1 World Revenues ($m) for Macrolides, 2008-2013, 2018 & 2023
• Table 7.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Macrolides, 2006 & 2013
• Table 8.1 World Revenues ($m) for Carbapenems, 2008-2013, 2018 & 2023
• Table 8.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Carbapenems, 2006 & 2013
• Table 9.1 World Revenues ($m) for Miscellaneous Drugs, 2008-2013, 2018 & 2023
• Table 9.2 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Miscellaneous Drugs, by Class, 2006 & 2013
• Table 10.1 A SWOT Chart for the Antibacterials Market, 2008-2013
• Table 11.1 Pipeline Drugs for Antibacterials, 2008
• Table 12.1 World Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013, 2018 & 2023
• Table 12.2 Top Ten Antibacterial Drugs, by Revenue ($m), 2006

List of Figures

• Figure 3.1 Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013
• Figure 3.2 Total Revenues ($m) for the Antibacterial Drugs Market, 2008-2013
• Figure 3.3 World Market Share (%) for Antibacterial Drugs by Class, 2006
• Figure 3.4 World Market Share (%) for Antibacterial Drugs by Class, 2013
• Figure 3.5 The Leading Top Ten Antibacterials by Revenue ($m), 2006
• Figure 4.1 Total World Revenues ($m) for Cephalosporin Drugs, 2008-2013
• Figure 4.2 World Revenues ($m) for the Cephalosporin Drugs by Leading Product, 2008-2013
• Figure 4.3 World Market Share (%) for Cephalosporin Drugs by Leading Product, 2006
• Figure 4.4 World Market Share (%) for Cephalosporin Drugs by Leading Product, 2013
• Figure 4.5 World Omnicef Revenues ($m), 2008-2013
• Figure 4.6 World Rocephin Revenues ($m), 2008-2013
• Figure 4.7 World Maxipime Revenues ($m), 2008-2013
• Figure 5.1 Total World Revenues ($m) for Fluoroquinolones, 2008-2013
• Figure 5.2 World Revenues ($m) for the Fluoroquinolones by Leading Products, 2008-2013
• Figure 5.3 World Market Share (%) for Fluoroquinolones by Products, 2006
• Figure 5.4 World Market Share (%) for Fluoroquinolones by Products, 2013
• Figure 5.5 World Levaquin Revenues ($m), 2008-2013
• Figure 5.6 World Avelox Revenues ($m), 2008-2013
• Figure 5.7 World Ciproxin Revenues ($m), 2008-2013
• Figure 5.8 World Cravit Revenues ($m), 2008-2013
• Figure 6.1 Total World Revenues ($m) for Penicillins, 2008-2013
• Figure 6.2 World Revenues ($m) for the Penicillins by Leading Product, 2008-2013
• Figure 6.3 World Market Share (%) for Penicillins, 2006
• Figure 6.4 World Market Share (%) for Penicillins, 2013
• Figure 6.5 World Augmentin Revenues ($m), 2008-2013
• Figure 6.6 World Tazocin Revenues ($m), 2008-2013
• Figure 7.1 Total World Revenues ($m) for Macrolides, 2008-2013
• Figure 7.2 World Revenues ($m) for the Macrolides by Leading Product, 2008-2013
• Figure 7.3 World Market Share (%) for Macrolides, 2006
• Figure 7.4 World Market Share (%) for Macrolides, 2013
• Figure 7.5 World Klacid Revenues ($m), 2008-2013
• Figure 7.6 World Zithromax Revenues ($m), 2008-2013
• Figure 7.7 World Azithromycin PFIZ Revenues ($m), 2008-2013
• Figure 8.1 Total World Revenues ($m) for Carbapenems, 2008-2013
• Figure 8.2 World Revenues ($m) for the Carbapenems by Leading Product, 2008-2013
• Figure 8.3 World Market Share (%) for Carbapenems, 2006
• Figure 8.4 World Market Share (%) for Carbapenems, 2013
• Figure 8.5 World Zienam Revenues ($m), 2008-2013
• Figure 8.6 World Merrem Revenues ($m), 2008-2013
• Figure 9.1 Total World Revenues ($m) for Miscellaneous Drugs, 2008-2013
• Figure 9.2 World Revenues ($m) for the Miscellaneous Drugs by Leading Product, 2008-2013
• Figure 9.3 World Market Share (%) for Miscellaneous Drugs by Leading Product, 2006
• Figure 9.4 World Market Share (%) for Miscellaneous Drugs by Leading Product, 2013
• Figure 9.5 World Zyvox Revenues ($m), 2008-2013
• Figure 9.6 World Targocid Revenues ($m), 2008-2013
• Figure 9.7 World Vancocin Revenues ($m), 2008-2013
• Figure 12.1 Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013

Companies Mentioned

• Abbott
• Agennix
• Arpida
• Asubio Pharma
• Basilea
• Bausch & Lomb
• Daiichi Sankyo
• Eli Lilly
• Enanta
• Flamel Technologies
• Genaera
• Genzyme
• Giaconda
• Gilead Sciences
• GSK
• Inhibitex
• InSite Vision
• Johnson & Johnson
• Leiden University
• Merck&Co
• MiddleBrook
• Migenix
• Neosil
• NovaBay
• Novartis
• Novexel
• Optimer
• Ortho-McNeil
• Otsuka
• Pathogenics
• Pfizer
• Pharming
• Photopharmica
• Procter & Gamble
• Rib-X
• Roche
• Schering-Plough
• Shogoo Pharmaceuticals
• Takeda
• Targanta
• Tekmira ; Aradigm
• Theravance
• Wakunaga
• Wockhardt
• Wyeth
• XOMA